London, UK; Brentwood, TN, US: 6 March 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that today, application has been made to the UK Listing Authority and the London Stock Exchange for the block listing of 259,014 ordinary shares of 2p each in the Company (the “Shares”) to be admitted to trading on the Official List and to trading on London Stock Exchange’s main market. The Shares will be used to fulfil the Company’s requirement to allot shares pursuant to the exercise of options under the terms of the Company’s 2005 Long-Term Incentive Plan and 2005 Deferred Bonus Plan.
